NCT02204098View on ClinicalTrials.gov

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 7, 2015

Primary Completion Date

April 6, 2022

Study Completion Date

August 31, 2028

Conditions
Breast CancerBreast CarcinomaMalignant Neoplasm of Breast
Interventions
BIOLOGICAL

Mammaglobin-A DNA Vaccine

PROCEDURE

Optional biopsy

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Rising Tide Foundation

OTHER

collaborator

United States Department of Defense

FED

lead

Washington University School of Medicine

OTHER